We are live on ! Find out more
BLRX

BioLineRX
BLRX

21 hedge funds and large institutions have $4.6M invested in BioLineRX in 2020 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

17% more funds holding

Funds holding: 18 → 21 (+3)

0.02% less ownership

Funds ownership: 0.03% → 0.01% (-0.02%)

31% less capital invested

Capital invested by funds: $6.66M → $4.6M (-$2.05M)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

Holders
21
Holders Change
+3
Holders Change %
+16.67%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
3
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PHP
Parkman Healthcare Partners
Connecticut
+$935K
2
Citadel Advisors
Citadel Advisors
Florida
+$108K
3
SFI
Susquehanna Fundamental Investments
Pennsylvania
+$89.7K
4
SSA
Schonfeld Strategic Advisors
New York
+$77.6K
5
LPL Financial
LPL Financial
California
+$56.8K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$2.77M
2
KCM
Kennedy Capital Management
Missouri
-$1.14M
3
SM
Senvest Management
New York
-$543K
4
O
OrbiMed
New York
-$114K
5
Morgan Stanley
Morgan Stanley
New York
-$78.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$1.84M -$78.9K -903 -5%
PHP
2
Parkman Healthcare Partners
Connecticut
$1.08M +$935K +10,699 New
Renaissance Technologies
3
Renaissance Technologies
New York
$673K -$612 -7 -0.1%
PVH
4
Psagot Value Holdings
Israel
$295K – – –
Citadel Advisors
5
Citadel Advisors
Florida
$124K +$108K +1,233 New
LPL Financial
6
LPL Financial
California
$108K +$56.8K +650 +154%
SFI
7
Susquehanna Fundamental Investments
Pennsylvania
$103K +$89.7K +1,026 New
SSA
8
Schonfeld Strategic Advisors
New York
$90K +$77.6K +888 New
CCB
9
Cutter & Co Brokerage
Missouri
$72K -$699 -8 -1%
TNB
10
Thomasville National Bank
Georgia
$51K +$17K +195 +62%
OM
11
Opaleye Management
Massachusetts
$42K – – –
RhumbLine Advisers
12
RhumbLine Advisers
Massachusetts
$36K +$31K +355 New
Creative Planning
13
Creative Planning
Kansas
$33K -$1.31K -15 -4%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$25K +$22.5K +257 New
UBS Group
15
UBS Group
Switzerland
$15K +$4.11K +47 +45%
NFG
16
Next Financial Group
Texas
$9K – – –
SPIA
17
Steward Partners Investment Advisory
New York
$3K +$2.45K +28 New
SFS
18
Sowell Financial Services
Arkansas
$1K +$437 +5 New
RE
19
RBC Europe
United Kingdom
$33 – – –
BI
20
BVF Inc
California
– -$2.77M -42,159 Closed
KCM
21
Kennedy Capital Management
Missouri
– -$1.14M -17,389 Closed
SM
22
Senvest Management
New York
– -$543K -8,280 Closed
O
23
OrbiMed
New York
– -$114K -1,731 Closed
Goldman Sachs
24
Goldman Sachs
New York
– -$39K -598 Closed
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
– -$262 -3 -60%

BLRX Hedge Fund Activity: Q4 2020 in Review

21 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2020, worth a combined $4.6M — down 31% from $6.66M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new BLRX positions and 5 closed out — a net gain of 3 holders — while 3 added to existing stakes and 5 trimmed.

The largest buyer was Parkman Healthcare Partners, opening a new position worth an estimated $935K. The largest seller was BVF Inc, exiting entirely with an estimated $2.77M sold.

  • 21 institutional investors held BioLineRX (BLRX) as of Q4 2020, up from 18 in Q3 2020.
  • Funds reported $4.6M of BioLineRX stock for Q4 2020, down 31% quarter-over-quarter.
  • 8 funds opened new BioLineRX positions in Q4 2020 and 5 closed out, a net change of +3 holders.
  • The largest BioLineRX buyer in Q4 2020 was Parkman Healthcare Partners, an estimated $935K added.
  • The largest BioLineRX seller in Q4 2020 was BVF Inc, an estimated $2.77M sold.

Based on aggregated 13F filings for Q4 2020.